Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875637 | 0.81 | MAPK14 (0.63) | MAPK14ADORA2AEGFRRAF1ADORA3 | |
| SCHEMBL5875504 | 0.79 | MAPK14 (0.77) | MAPK14ADORA2AEGFRRAF1ADORA3 | |
| SCHEMBL5457630 | 0.78 | MAPK14 (0.63) | MAPK14ADORA2APOLBEGFRRAF1 | |
| SCHEMBL5875497 | 0.75 | MAPK14 (0.61) | MAPK14ADORA2AEGFRRAF1ADORA3 | |
| SCHEMBL5453371 | 0.69 | ALOX5 (0.43) | MAPK14ADORA2AADORA3ADORA1KDM4E | |
| SCHEMBL5379814 | 0.69 | MAPK14 (0.61) | MAPK14ADORA2APOLBEGFRRAF1 | |
| SCHEMBL18189934 | 0.69 | MAPK14 (0.42) | MAPK14POLBGSK3BPTGS2 | |
| SCHEMBL18189859 | 0.68 | GRIA1 (0.51) | KDM4ELMNAMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL5452978 | 0.66 | MAPK14 (0.72) | MAPK14ADORA2AEGFRRAF1ADORA3 | |
| SCHEMBL5398429 | 0.64 | MAPK14 (0.63) | MAPK14ADORA2APOLBEGFRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109209-B2 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | ALBERTI MICHAEL J | 2006-03-16 | — | — | US | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| EP-1372643-A1 | PYRAZOLOPYRIDINES, PROCESS FOR THEIR PREPARATION AND USE AS THERAPEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-1372642-A1 | USE OF PYRAZOLOPYRIDINES AS THERAPEUTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002078700-A1 | PYRALOPYRIDINES, PROCESS FOR THEIR PREPARATION AND USE AS THERAPTEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002078701-A1 | USE OF PYRAZOLOPYRIDINES AS THERAPEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP3A7 | MAPK14 2256/4885PDE4B 83/4885ADORA2A 1622/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | MAPK14 1551/4885PDE4B 306/4885ADORA2A 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.